Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
This study is testing a new combination of two drugs, SAR444881 and cemiplimab, to see how well they work against solid tumors. Researchers want to understand specific biological signs, called biomarkers, that show how the body responds to these treatments.
You may be able to join if you are 18 or older and have an advanced tumor or cancer that has spread. However, you cannot join if you are pregnant, have certain active immune system disorders, or have severe allergies to similar medications.
Participants will receive the study medications and have regular check-ups with the medical team to monitor their health and response to the treatment. The team will also look closely at biological samples to learn how the drugs are working.
This study is currently open and actively looking for participants. It is taking place in Houston, Texas, in the United States.
- 1Tests an investigational drug combined with an immunotherapy treatment
- 2Open to adults with advanced solid tumors or cancers
- 3Currently recruiting patients in Houston, Texas
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.